Smart bomb for leukemia: new combo targets tough cancers
NCT ID NCT06034470
First seen Feb 24, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This early-phase study tests a new targeted drug (PVEK) combined with standard chemotherapy for adults with aggressive forms of acute myeloid leukemia and related blood cancers. PVEK works like a smart bomb, attaching to cancer cells and delivering chemotherapy directly to them. The goal is to find the safest dose and see if this combination works better than standard treatment alone. About 30 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.